Studies of streptozotocin-induced diabetes in rats have demonstrated that hepatic apo B and apo E production are reduced. To determine if reductions are related to decreases in hepatic mRNAs, we performed blotting analysis of total liver RNA with rat apo B, apo E, and albumin cDNA probes. The expected reduction in albumin mRNA levels to 48% of control livers occurred in diabetic rat liver, while apo B and apo E mRNA levels were unchanged. The proportion of translational stop codon (BSTOP) mRNA averaged 43% of total in diabetic rats similar to control levels. Long-term labeling experiments using JISlmethionine in primary cultures of rat hepatocytes and specific immunoprecipitations demonstrated production of apo B and apo E, and albumin by hepatocytes from diabetic rats was reduced to 37%, 53%, and 23% of controls. Pulse-chase studies, together with mRNA analyses, suggest that reduced hepatic secretion of apo B and apo E in diabetics is primarily a result of impaired translation and not intracellular degradation. Ribosome transit studies directly confirmed the prolonged elongation rates for apo B and apo E mRNAs in hepatocytes derived from diabetic rats. This effect was more pronounced on apo BH (higher molecular weight) than on apo BL (lower molecular weight). Treatment of diabetic rats with insulin for 7 d led to normalization of hepatic albumin mRNA levels with no substantial change in apo E mRNA levels. In contrast, insulin treatment resulted in significant increases in hepatic apo B mRNA over control levels. Results suggest hepatic albumin and apo B mRNA levels are responsive to insulin in the diabetic state. (J.
Introduction
Hormonal and metabolic regulation ofapo synthesis and lipoprotein assembly is complex (1) . Since the liver is a major source ofplasma lipoproteins (2) , factors affecting hepatic lipoprotein production are important to our understanding of the mechanisms involved in the development ofhyperlipoproteinemias. Although there are numerous studies of specific hormone effects on VLDL production by liver, we have focused on apo B, not only because apo B is a requisite component of VLDL and LDL (3) , but also because measurement of apo B gives an estimate of number of lipoprotein particles secreted (4) . In humans (5) and rats (6) (7) (8) there are two forms ofapo B, one of higher molecular weight (B-100, apo BH)' and one of lower molecular weight (B-48, apo BL). The two forms ofapo B are derived by a novel editing process (9-1 1) which converts a glutamine codon within the apo B mRNA (BGLN) to a translational stop codon (BSTOP) at position 2153 in humans. Because of apo B mRNA editing, a shorter translation product is synthesized representing -48% ofthe molecular weight ofthe complete translation product. B-100 is the predominant form of apo B produced by human liver (12, 13) whereas both apo BH and apo BL are produced by rat liver (6) (7) (8) 14) . In rats and humans, apo BL (B-48) is the predominant form of apo B produced by the intestine (5, 14) . Distinctive features of triglyceride-rich lipoproteins containing apo BL (hepatic and intestinal) are their shorter plasma residence time (6, 14, 15) and their failure to be converted to LDL (15) .
Hormonal and metabolic control ofhepatic apo B synthesis and secretion can occur at a number oflevels involving changes in apo B mRNA abundance (16) (17) (18) , apo B mRNA editing (18) (19) (20) , and through alterations in intracellular apo B degradation (21-24). Hepatic apo B mRNA abundance is increased by 30% in experimentally hypothyroid rats (16) , by 50% in hypothalamus-lesioned obese rats (17) , and by 80% in 48-h fasted rats (18) . Apo B mRNA editing is dramatically increased by thyroid hormone injection ( 16, 19) and by refeeding fasted rats with a high carbohydrate diet (18) . In rats fasted for 48 h, hepatic apo B mRNA editing is significantly reduced (18, 20) . Existing evidence suggests that hepatic apo B secretion can also be affected posttranslationally through degradation of freshly synthesized apo B (21) (22) (23) (24) . Insulin has been shown to reduce hepatic secretion of apo B (22, (25) (26) (27) (28) by stimulation of intracellular degradation (22) .
In order to understand the complex role ofinsulin in regulation of hepatic apo B production we have examined the effects ofhypoinsulinemic diabetes (28, 29) . This experimental model is of interest because diabetic rats develop significant hyperlipidemia (30) (31) (32) along with increased levels of plasma apo Bcontaining lipoproteins (29, 31) . The cause of the hyperlipidemia has been attributed to overall increase in lipoprotein formation (31, 32) in combination with defective peripheral and hepatic catabolism of triglyceride-rich lipoproteins and LDL (29, (31) (32) (33) (34) (35) . VLDL composition is altered in streptozotocin-induced diabetes with a marked reduction in apo E content (29, 31, 36) which may be a contributory factor to the catabolic defect, as apo E is an important ligand for hepatic lipoprotein receptors (37). Hepatic secretion of VLDL lipid (36, (38) (39) (40) (41) and apo B and E is substantially reduced in both primary cultures of hepatocytes (28, 29) and perfused livers derived from diabetic rats (28, 36) . These findings suggest that the hyperlipidemia of experimental diabetes is primarily a result of the accumulation of intestinally derived chylomicrons and VLDL, and suggest further that the contribution of apo B-containing lipoproteins to the plasma by the liver in the hypoinsulinemic diabetic state is relatively small. Considering that the liver in most circumstances is the major source ofplasma VLDL, these findings suggest that endogenous insulin is required for normal hepatic VLDL apo B production. Furthermore, since the majority ofplasma apo E is hepatically synthesized (2) and there is a substantial reduction in hepatic apo E secretion in hypoinsulinemic diabetes (29, 36) , it follows that insulin may also be involved in normal hepatic apo E production.
The major objective ofthe present study was to determine if the reduced hepatic secretion ofapo B and apo E in experimental diabetes is due to a reduction in apolipoprotein mRNA, to a reduction in apolipoprotein synthesis, or to enhanced intracellular degradation of freshly synthesized apolipoproteins. An additional objective was to evaluate the effect of insulin treatment ofthe diabetes on hepatic apo B and apo E mRNA levels. Our results indicate that hepatic apo B and apo E mRNA abundance in livers ofdiabetic rats is not decreased correspondingly with reduced apolipoprotein synthesis. In contrast, both hepatic albumin mRNA and albumin synthesis are correspondingly reduced in diabetic rats. Using primary cultures of hepatocytes derived from diabetic rats, evidence is presented that translational defects at the level of peptide elongation of both apo B and apo E mRNAs underlie the hypoinsulinemic effect. Insulin treatment ofdiabetic rats resulted in the normalization of hepatic albumin mRNA levels while apo E mRNA levels were unchanged compared with diabetic rats. In contrast, hepatic apo B mRNA increased to 1.9 times that of untreated diabetic rats by insulin treatment. These results indicate that insulin therapy did not act in a generalized fashion to increase all hepatic mRNAs, and suggest that albumin and apo B messages in rat liver are responsive to insulin treatment of the diabetic state.
Methods
Animals. Male, Sprague Dawley rats (225-250 g) were used for the study. Rats were fasted overnight and made diabetic by injection of streptozotocin (85 mg/kg) dissolved in 0.01 M citrate buffer, pH 4.5 (29) . Control rats were injected with citrate buffer alone. After injection, the animals were refed and allowed access to food and water ad lib. Urine was tested daily for 10 d for the presence of glucose and ketones, using Ames Keto-Diastix. Animals were not acidotic as evidenced by measured electrolytes (Na+, K+, CO2, Cl-). After 10 d, half of the diabetic rats were treated by a single, daily, subcutaneous injection ofprotamine zinc insulin (20 U/kg; Eli Lilly and Co., Indianapolis, IN) at 3:00 P.M. After 7 d of insulin treatment, fed rats were anesthetized with sodium pentobarbital (25-40 mg/kg) and exsanguinated via the abdominal aorta. Livers were immediately removed, weighed, frozen in liquid nitrogen, and stored at -800C before RNA isolation. Liver weights (g) of diabetic rats were significantly less than either the control or treated diabetic rats (P < 0.001) and averaged (±SD) 10 .5±0.97 (n = 7) compared with 13.3±1.37 (n = 11) in control rats and 13.6±2.00 (n = 7) in treated diabetic rats. Serum was prepared from blood, and the following serum parameters were measured to characterize animals, including glucose, insulin, apo B, cholesterol, triglyceride, and alanine amino transferase (ALT), as previously described (29) . Triiodothyronine (T3) was determined by radioimmunoassay (42), and thyroxine (T4) and free thyroxine (free T4) were assayed by fluorometric enzyme immunoassay (43) .
Isolation ofRNA. Frozen rat livers were placed into ice-cold buffer containing 5 M guanidinium thiocyanate, 50 mM Tris-HCl buffer (pH 7.5), 25 mM EDTA, and 8% 2-mercaptoethanol (44), and were homogenized at the highest setting for 30 s using an instrument (Tekmar Co., Cincinnati, OH). RNA was isolated from the homogenate by successive ethanol precipitation in the presence of 6 M guanidine hydrochloride. The final RNA precipitate was dissolved in autoclaved diethyl pyrocarbonate-treated water and stored at -70'C until analysis. The ratio of absorbances at 260 nm and 280 nm averaged 1.8 or greater in each group of rats. The yields of total liver RNA averaged (milligram/ gram liver, mean±SD): 4.3±1.00 (n = 11) in the control group; 4.3±0.48 (n = 7) in the diabetic group; and 5.2±0.78 (n = 7) in the treated diabetic rat group.
DNA probes. The double stranded cDNA probe for apo B was a 2900-bp cDNA fragment from the 3' region of rat apo B mRNA (45) , and was kindly provided by Dr. A. J. Lusis at the University ofCalifornia, Los Angeles. Apo E cDNA of -900 bp was kindly provided by Dr. L. Chan, Baylor College ofMedicine, Houston, TX. The f-actin probe was a 3400-bp DNA fragment of the mouse ,B-actin gene that was provided by Dr. D. Friedman, University of Texas, San Antonio. The rat albumin probe was a full length cDNA probe provided by Dr. T. Sargeant, National Institutes of Health, Bethesda, MD. The ribosomal cDNA, a 1400-bp fragment that detects the 28S ribosomal subunit, was supplied by Dr. J. Sylvester, Hahnemann University, Philadelphia, PA. DNA probes were labeled with 32P to a specific activity of greater than 108 cpm/Ag DNA, using [32P]dCTP (> 3000 Ci/mmol specific activity) and the random primer method (46).
Blotting analysis of RNA. Total RNAs were size fractionated on formaldehyde denaturing agarose gels by electrophoresis (47) , and separated RNAs were transferred to Nytran membranes (Schleicher and Schuell, Inc., Keene, NH), following the manufacturer's protocols (48) . For dot blots, total RNA was made 6x standard saline citrate (SSC) and 7% formaldehyde, heated at 60°C for 15 min, and applied in duplicate at two different concentrations of RNA (5 and 10 Mg) to Nytran membranes using a Millipore 96-well manifold. After baking the membranes at 80°C for 2 h to fix RNA, membranes were prehybridized, hybridized with labeled probes (49) , and then strigently washed to remove nonspecifically bound probe (final conditions were 0.1X SSC and 57°C). Nytran membranes were autoradiographed using XAR-5 film (Eastman Kodak Co., Rochester, NY) with intensifying screens (Lightning-Plus; Dupont Co., Wilmington, DE) for varying lengths of times at -70°C to assure that signals were within the linear range ofthe film. Relative signal intensities of autoradiograms were measured by densitometry. The signal obtained from hybridization with the f3-actin DNA probe was not significantly different in control, diabetic, and treated-diabetic rat groups, and averaged (signal intensity±SEM): 262±30 in the control group; 231±51 in the diabetic group; and 202±56 in the treated-diabetic group, respectively.
Measurement of edited apo B mRNA. (> 800 Ci/mmol) also in methionine-free medium. Incubation was continued for exactly 10 min, after which the medium from each dish was quickly withdrawn, monolayers were washed three times, and then reincubated for 10, 20 , and 180 min in 2.0 ml of Waymouth's MB 752/1 containing 0.2%, wt/vol, BSA and 10 mM L-methionine (chase medium) before termination.
Freshly synthesized apolipoproteins were estimated from the average label incorporated into cellular apolipoproteins at 10 and 20 min. Percent recovery of apolipoproteins was calculated as the amount of apolipoprotein label recovered in cells plus media at 180 min divided by the amount of freshly synthesized apolipoproteins, as described previously (22 Antibodies. Rabbit anti-rat serum albumin (IgG fraction) was obtained from Organon Teknika Corp., West Chester, PA. Rabbit antirat apo B was prepared by immunization of rabbits with SDS-column purified rat apo B, as described in detail elsewhere (22) . Rat apo E was prepared from VLDL isolated by ultracentrifugation of plasma (d < 1.006 g/ml) obtained from rats fed a 60%, wt/wt, sucrose diet (ICN Nutritional Biochemicals, Cleveland, OH) for 2 wk. The VLDL was dialyzed against saline and delipidated (52), and apolipoproteins were dissolved in 5 M urea, 2 mM sodium phosphate, I mg/ml dithiothreitol, and 0.01% sodium azide pH 7.4. Apo E was isolated by heparinagarose affinity chromatography (53) . To the salt fraction containing rat apo E, SDS was added (final concentration, 0.1%, wt/vol), and the sample was dialyzed overnight at room temperature against 6-10 liters of saline containing 0.1% SDS, wt/vol, using a 1 5,000-mol wt cut-off dialysis membrane. After dialysis, the sample was lyophilized and dissolved in Tris-buffer containing 2% wt/vol, SDS, 5% vol/vol, 2-mercaptoethanol, and 10mM dithiothreitol and chromatographed on SDS columns (54) . Column fractions containing purified apo E were determined by molecular weight analysis of the fractions using SDS-PAGE and stained gels (22) . After removal ofmost ofthe detergent by dialysis against a mixed bed ion exchange resin, apo E-containing fractions were lyophilized and used to immunize rabbits using the same protocol described for apo B immunizations (22) . Antisera was tested for antirat apo E activity by immunodiffusion and western blot analysis (55).
Immunoprecipitation ofcellular and media proteins. Hepatocytes were solubilized by scraping cells (-1 mg protein per ml ofbuffer) into solubilization buffer consisting of 0.05 M Tris buffer, pH 7.3, 0.15 M NaCl, 0.5% wt/vol, SDS, 1% vol/vol, Triton X-100, 10 mM EDTA, 10 mM EGTA, 5 mM benzamidine (freshly added), and 2 mM alpha-toluene sulfonyl fluoride (a-TSF) (freshly added). Homogenates were heated (80-90'C) for 1 h and spun at room temperature at 2700 x g (relative centrifugal force) for 20 min to remove debris. An aliquot of the supernatant was then diluted two times its volume with a diluent consisting of0.05 M Tris buffer, pH 7.3,0.15 M NaCl, 5 mM EDTA, 5 mM EGTA, 0.5% wt/vol, BSA, 2 mM a-TSF (freshly added), 2 mM benzamidine (freshly added), 10 Mg aprotinin/ml, 2 Ag/ml leupeptin, and 100 Mg/ml soy bean trypsin inhibitor. Media samples were mixed with an equal volume of solubilization buffer and diluent. Specific antiserum was then added to each diluted cell and media sample at a concentration shown to optimally precipitate proteins. Immunoprecipitations were carried out overnight at 4°C with mixing, and immune complexes were collected by addition of purified Protein A cells (22) . Protein A pellets were washed six times by resuspension in cold (4°C) 0.05 M Tris buffer, pH 7.3 containing 0.25% vol/vol, Triton X-100, 0.1% wt/vol, sodium lauryl sarcosine, 0.1% wt/vol, BSA, 0.6 mM EDTA, 0.6 mM EGTA, 2 mM benzamidine (freshly added), and 1 mM a-TSF (freshly added). Protein A-bound proteins were eluted into Tris buffer containing 2% wt/vol, SDS, 5% vol/vol, 2-mercaptoethanol, 10 mM dithiothreitol, 20% vol/vol, glycerol, and heated twice to 95°C for 5 min (22) . Protein A cells were removed by final centrifugation, and an aliquot of the eluate was radioassayed while another aliquot was electrophoresed on 3.5%-24% acrylaide'/acrylamide gradient gels cast on GelBond' PAGE film (22) . Labeled protein bands were visualized by fluorography using preflashed Kodak XAR-5 film at -80°C after the gels were fixed and subsequently enhanced with Autofluor' (22) . The ratio ofapo BH and apo BL label ofcells and media was assessed by scanning densitometry of films exposed to enhanced gels.
Ribosome transit time measurements. Ribosome transit times were measured in primary cultures of rat hepatocytes, using the method of Fan and Penman (56) mg/liter cycloheximide, 1% vol/vol, Triton X-100; 1%, wt/vol, sodium deoxycholate; 5 mM benzamidine (freshly added), 2 mM a-TSF (freshly added), 10 Mg/ml leupeptin, 100 ,g/ml soybean trypsin inhibitor, and 40 U/ml aprotinin. The cells were scraped from the dish with a teflon scraper and homogenized with five to seven strokes of a glassglass tissue grinder. Each cell homogenate was then recombined with its corresponding labeling media to insure that all ofincorporated radioactivity was recovered in the sample. The sample background was determined for each experiment by adding an unlabeled cellular homogenate to fresh experimental media containing both [3H] and ['4C]leucine (58) . Samples (homogenates plus medium) were centrifuged at 10,000 g at 4°C for 10 min to prepare postmitochondrial supernatants. Postribosomal supernatants were prepared by subsequent centrifugation at 50,000 rpm (230,000 g) at 4VC in a 70.1 Ti rotor using an ultracentrifuge (L7-65; Beckman Instruments, Inc., Fullerton, CA). To aliquots (200-500 Al) ofthe postmitochondrial and postribosomal supernatants were added 250 Al of 0.1 M L-leucine in 0.01 N HCl, and total and completed proteins were precipitated in 7.5% wt/vol TCA. Samples were then placed in a glass bead bath and heated at 95-100I C for 1 h, and then centrifuged. Precipitates were washed three to five times with 2 ml of 5% wt/vol TCA containing 1O mM L-leucine. After final centrifugation, supernatants were completely aspirated and pellets were dissolved in 0.3 ml Solvable' tissue and gel solubilizer (DuPont Co., New England Nuclear Research Products, Boston, MA). For ,3-counting, 0.25 ml of the dissolved TCA pellet was mixed with 0.25 ml distilled water and 5.0 ml of Formula 989 liquid scintillation cocktail (New England Nuclear). Immunoprecipitation of completed apo B, apo E, and albumin from postribosomal supernatants were performed essentially as described above, except that postribosomal supernatants were adjusted before overnight incubation with antibody by the following additions (final concentrations): 0.15% wt/vol, SDS, 13 mM EGTA; 13 mM EGTA, 0.33% wt/vol, BSA, 50 mM Tris-HCI, 5 mM benzamidine (freshly added), and 2 mM a-TSF (freshly added). Immunoprecipitates were washed and eluted as described above. For (-counting, a 50-Mi aliquot of eluted radiolabeled proteins was mixed with 450 MI distilled water and 5.0 ml Formula 989 liquid scintillation cocktail.
For transit time calculations, the ratio of tritium to carbon-14 was plotted against time after addition of L-[4,5-3H]leucine for the postmitochondrial protein (released plus incomplete polypeptides), postribosomal proteins (released), apo B (released), and apo E (released). Equations of the lines were determined by least-squares fit analysis. From the equations of the lines, x intercepts were calculated and half transit times were determined by subtracting the postmitochondrial x intercept from the x intercepts calculated from the lines of the other proteins. Since the average nascent chain is theoretically half completed after the addition ofthe first radioactive leucine, the observed half-transit times were doubled to give total transit times (56, 57) .
Liquid scintillation counting. Liquid scintillation counting was performed using a refrigerated (3-counter (Tri-Carb 4640; Packard Instruments Co., Downers Grove, IL). For measurement of "S-radioactivity, samples were counted to within 98% confidence limits. The ratios of3H and 14C were corrected for quenching in each channel, using the automatic quench correction derived from experimentally derived quench curves and after subtraction of the appropriate background. 3H-radioactivity was counted to within 98% confidence, while '4C-radioactivity was counted to within 95% confidence limits.
Results
Characterization ofanimals. Because ofindividual animal variability in response to streptozotocin and insulin treatment, rats were fully characterized to make certain that liver donors for mRNA analysis had the associated biochemical features of a severe diabetic state, and that treated diabetic rats showed evidence of reversal of the diabetes. In addition to serum insulin quantitation to document the diabetic state, thyroid status was evaluated. As seen in Table I , diabetic rats were characterized by significant hyperglycemia and hypoinsulinemia. Serum cholesterol and triglycerides were significantly elevated in diabetic rats consistent with increased levels of serum apo B. Serum ALT was elevated in diabetic rats as reported previously (29) . Thyroid hormone levels and free T4 were significantly reduced in diabetic rats but normalized with insulin therapy.
Effect of diabetes on liver apo B and apo E mRNA. To determine if the reductions previously observed in hepatic apo B and apo E secretion in streptozotocin diabetes correlated with decreased hepatic mRNAs, we compared mRNA levels in livers from control and diabetic rats (Table II) . When northern blots of liver RNA were hybridized with the 32P-labeled apo B cDNA probe, patterns were essentially identical to previous Table II , the amount of liver apo B and apo E mRNA was similar in control and diabetic rats.
To confirm the significance of the apo B and apo E mRNA results, total liver RNA was also hybridized with a labeled cDNA probe for rat albumin (Table II) . Albumin mRNA was chosen for analysis because it has been shown to be reduced in liver relative to total mRNA in experimental diabetes in rats (59) . As seen in Table II , relative albumin mRNA levels were significantly reduced to an average of 48% of control values in untreated diabetic rats. Effect of diabetes on apo B mRNA editing. The extent of apo B mRNA editing was determined using competimer PCR ofapo B mRNA isolated from control and diabetic rat liver. In control livers, the amount of BSTOP averaged 46±5% (SD, n = 6). In three livers from diabetic rats, BSTOP was 31%, 47%, and 52% of the total apo B mRNA, and averaged 43%±11% (SD). These analyses suggest that livers derived from diabetic rats contain control levels of BSTOP and BGLN mRNA.
Effect ofdiabetes on net apo B synthesis byprimary cultures ofhepatocytes. In order to determine ifthe previously observed reduction in apo B secretion by livers derived from diabetic rats was due to an effect on apo B translation, we examined apo B synthesis in corresponding cultures ofprimary rat hepatocytes. We have previously demonstrated that the reduced hepatic secretion of apo B by liver of diabetic rats is retained by corresponding primary hepatocytes (28, 29) . Liver perfusions to prepare hepatocytes were carried out 1 h apart so that hepatocytes derived from control and diabetic livers could be cultured under identical experimental conditions. Hepatocytes were labeled 12-14 h with [35S]methionine and labeled apo B of cell lysates and media ofcontrol, and diabetic hepatocytes was immunoprecipitated and quantitated (Table III) . Assuming that cells labeled for 12-14 h have approached constant specific activity, the apo B label present in cells reflects apo B mass (22) . Results from four experiments indicate that the cellular pool of apo B in hepatocytes derived from diabetic rats is, on average, 56% of that of control levels. This result is consistent with our previous report which indicates that the cellular pool of apo B of hepatocytes derived from diabetic rats was significantly reduced compared with controls using a monoclonal radioimmunoassay which measures an amino terminal-specific epitope present on both apo BL and apo BH (29, 55 ). Labeled apo B ofcell and media isolated by immunoprecipitation was separated into apo BH and apo BL by SDS-PAGE (Fig. 1) . In hepatocytes from control rats, cellular apo B radioactivity was present in both apo BH and apo BL fractions. The ratio of cellular apo BL to apo BH radioactivity averaged 4.2±1.0 (SD). Assuming the mass of apo BL is 48% of apo BH, the molar ratio of cellular apo BL to apo BH in hepatocytes of control rats is about 8-9 to 1 consistent with our previous report (22) . In hepatocytes derived from four diabetic rats, the cellular apo B label was mostly apo BL having an estimated labeling ratio of apo BL to apo BH of 23.7±8.4, giving a calculated molar ratio of about 49 to 1.
In 12-14-h labeled hepatocytes derived from control rats the ratio of labeled apo BL to apo BH which was secreted averaged 2.4±0.72 (SD). On a molar basis this suggests that for every apo BH particle secreted, three to seven particles of apo BL are secreted. In contrast, apo B label in 12-14 h labeling media of hepatocytes derived from four diabetic rats demonstrated mainly apo BL having an estimated labeling ratio ofapo BL to apo BH of 13.0±4.8, giving a calculated molar ratio of about 27 to 1. These results suggest that the net production of apo BH-lipoproteins in 12-14 h cultures by hepatocytes derived from diabetic rats is significantly depressed.
Effect ofdiabetes on net apo B, apo E, and albumin synthesis by primary cultures ofhepatocytes. In order to compare the effect of streptozotocin-diabetes on net apo B, apo E, and albumin synthesis, immunoprecipitations were carried out with specific polyclonal antibodies (Fig. 2) gate during the chase after addition of excess "cold" methionine. In both the diabetic and control this plateau is evident, as there is equivalency ofthe 10-and 20-min postlabeling cellular apo B label. At 10 min into the chase, there is full-length apo B in control as the chase exceeds the transit time. Fluorographs of apo B immunoprecipitates of hepatocytes derived from diabetic rats suggest that they contain partially translated apo B (Fig. 3) at 10 min that becomes fully elongated in the chase period as a result of slower, overall translation (Table V) (Fig. 3) . The reduced labeling ofapo B is an indication of slower translation in hepatocytes derived from diabetic rats. The form of apo B synthesized by hepatocytes derived from diabetic rats was predominantly apo BL (Fig. 3 ) even during longer times in the chase period to allow for full elongationlofapo BH (data not shown). Apo BL label did not disappear from cells even after 180 min of chase in either control hepatocytes or in hepatocytes derived from diabetic rats consistent with the presence ofa cellular pool of apo BL (Fig. 3 ) as previously described (22) . In similar pulse-chase studies of apo E, using paired cultures of hepatocytes derived from control and diabetic rats, incorporation of label into apo E by hepatocytes derived from diabetic rats was only 25% and 35% of that incorporated by hepatocytes derived from control rats in two paired experi- ments. In contrast to apo BL, apo E labeled during the pulse period disappeared completely from the cell during the 180 min of chase both in hepatocytes derived from control and diabetic rats (Fig. 4) . This result for apo E is similar to that observed for apo BH in that pulse-labeled apolipoprotein disappears completely during the chase period (Fig. 3) . Apolipoprotein degradation in hepatocytes derivedfrom diabetic rats. The amount ofintracellularapolipoprotein degradation by hepatocytes was calculated as the difference in the amount of fully translated labeled apolipoprotein during the pulse-labeling period, and the amount of labeled apolipoprotein recovered in cells and media at 180 min ofchase. In hepatocytes derived from three diabetic rat livers, the recovery of freshly synthesized apo BL averaged (±SD): 84%±6.4%. Apo BL recovery in hepatocytes derived from diabetic rats did not differ significantly from that previously observed in hepatocytes derived from control rats using similar methods (22) . Since most freshly synthesized apo BL is recovered in hepatocytes derived from diabetic rats, the reduction in apo BL secretion by these cells is not primarily due to enhanced intracellular degradation. Hepatocytes derived from diabetic rats synthesized little full-length apo BH which was inadequate to assess apo BH recovery.
In two paired experiments to measure apo E recovery, an average of 85% and 93% offreshly synthesized apo E was recovered in hepatocyte cultures derived from control and diabetic rats, respectively. Since most freshly synthesized apo E was recovered in hepatocytes derived from diabetic rats these results suggest that intracellular apo E degradation is not a major factor in the reduced hepatic apo E secretion observed in hepatocytes derived from diabetic rats.
Effect ofdiabetes on average ribosome transit times. Average ribosome transit times were measured in primary cultures of hepatocytes derived from control and diabetic rats, using essentially the method described by Palmiter (57 and the number of polyribosomes (57) . Moreover, using the dual-labeling method (long-and short-term label) and isotope ratios, the method is independent of sample size and recovery. Selective loss of protein due to secretion was eliminated by combining cell homogenates with corresponding media which insures that all incorporated label is present in the sample (58) . Ratios of 3H to 14C of postmitochondrial and postribosomal supernatants at each time point were analyzed using TCA precipitation, whereas the ratios for apo B and apo E were determined by specific immunoprecipitations from postribosomal supernatants. The validity of the dual-label method depends upon the ability to separate completed from incomplete polypeptides bound to polyribosomes. In Fig. 5 , separation ofcompleted apo B and apo E in the postribosomal supernatant is compared with incomplete apo B polypeptides which were immunoprecipitated from the polysome pellet. Half-ribosome transit times of total soluble protein were determined by the displacement in time of postribosomal and postmitochondrial supernatant proteins. Half-ribosome transit times for apo B and apo E were calculated from the displacement in time of each protein from the total protein synthesized in postmitochondrial supernatants (Fig. 6) . Calculated ribosome transit times in control hepatocytes for total soluble protein, apo B and apo E averaged 3.6, 9.3, and 3.1 min, respectively. There were prolonged ribosome transit times of total soluble protein, apo B and apo E, in hepatocytes derived from diabetic rats which averaged 6.7, 38, and 8.1 min, respectively. Effect of insulin treatment in vivo on selected RNAs in rat liver. To determine the effect of in vivo insulin treatment ofthe diabetic state on hepatic apolipoprotein mRNAs, diabetic rats were treated by daily subcutaneous injection of protamine zinc insulin for 7 d before liver RNA analysis. Blotting analyses of total liver RNA with rat apo B, apo E, and albumin cDNAs were performed on diabetic rats and on rats with documented reversal of the diabetic state (normal glucose, insulin, and ALT). Data are expressed as percent of the control to allow direct comparisons to be made of diabetic and treated diabetic rat liver mRNAs (Table VI) was added and cultures were reincubated and terminated at the times indicated. Postmitochondrial supernatants were prepared, followed by centrifugation to remove polysomes and nascent incompleted polypeptides. Ratios of 3H to '4C in postmitochondrial supernatants were determined by TCA precipitation. Ratios of 3H to '4C in specific proteins were determined after immunoprecipitation from postribosomal supernatants, using specific polyclonal antisera as described in Methods. Postmitochondrial supernatants consisting of completed and polysome bound polypeptides are plotted as solid circles. Released apo B and apo E peptides are indicated as solid squares and triangles, respectively.
in the cell. As seen in Table VI , hepatic apo E and ,B-actin mRNA levels and ribosomal 28S RNA ofdiabetic rats were not significantly different than those in livers of insulin-treated rats. In contrast, insulin treatment of diabetic rats resulted in increases in hepatic apo B and albumin mRNAs which were 1.9 and 2.5 times the value obtained in untreated diabetic rats. The increase in apo B mRNA represents a significant increase over the control value in contrast to albumin.
Discussion
Previous studies of streptozotocin-induced diabetes in rats have shown that in liver perfusions, hepatic VLDL-lipid (36, (38) (39) (40) and apo B and apo E secretion (28, 36) are reduced, and (38, 63) could explain the more pronounced effect of insulin-deficiency on synthesis of secretory proteins, compared with the synthesis of cellular proteins which are translated primarily on free polyribosomes. It would be predicted that the reduction in secretory protein synthesis and secretion would be a general effect observed for all secretory proteins. There does, however, appear to be disproportionate change in the synthesis of certain secretory proteins, particularly glycoproteins (65) including alpha-1-acid-glycoprotein of Darcy (66).
To determine whether a translational mechanism is involved in the reduced secretion of hepatic apo B and apo E in hypoinsulinemic diabetes, we compared their synthesis using long-term labeling (12-14 h ) in primary cultures ofhepatocytes derived from control and diabetic rats (Table IV) . The specific activity of cellular and media apo B in hepatocytes derived from control, and diabetic rats were similar supporting the idea that the extent oflabel incorporation reflects amount ofprotein present. In these comparative studies the production of apo B, apo E, and albumin is reduced by the diabetic state to 44%, 53%, and 23%, respectively, of control levels. In addition, the hepatic pool of apo BL in hepatocytes derived from diabetic rats is significantly reduced, compared with control hepatocytes.
Long-term labeling studies reflect "net" apolipoprotein production, and, therefore, do not measure synthesis or extracellular catabolism directly. Previous studies in control cultures which measured degradation of radioiodinated lipoprotein added to media indicate that 15% of added lipoprotein is degraded in 18-h cultures (25). In our studies using nonfasted, radioiodinated triglyceride-rich lipoprotein (d < 1.006 g/ml, VLDL including remnants) and low density lipoprotein (1.019 < d < 1.063 g/ml including IDL), 27% ofTRL and LDL apo B were degraded over 16 h in culture (29) . In hepatocytes derived from diabetic rats, the degradation ofapo B ofTRL and LDL is significantly reduced to -10% (29) . As hepatocytes derived from diabetic rats degrade less lipoprotein added to media than control cells, it is unlikely that the observed reduction in lipoprotein production by hepatocytes derived from diabetic rats is the result of increased postsecretory catabolism by these cells.
To study impairment in translation in diabetes, we examined apo B and apo E synthesis and secretion using a pulsechase protocol in primary cultures of hepatocytes. Using a short period ofincubation with [35Sjmethionine label (10 min), and by measuring incorporation into apolipoproteins early in the chase period before secretion takes place, an estimate of apolipoprotein synthesis can be made directly (22) . The impairment in apo B and apo E synthesis by hepatocytes derived from diabetic rats was apparent, as label incorporated into apo B and apo E was reduced to 39% for apo B and 30% for apo E compared with control hepatocytes. Both long-term and pulsechase studies suggest impairment of hepatic apo B and apo E translation in streptozotocin-diabetic rats. To rule out the possibility that reduced hepatic production of apo B and apo E was due to posttranslational, intracellular degradation before secretion, we measured the recovery of pulse-labeled apolipoproteins after 180 min of chase. Our results demonstrate that greater than 84% and 93% of freshly synthesized, full length apo BL and apo E, respectively, were recovered in media, plus hepatocytes derived from diabetic rats. These results suggest that posttranslational, intracellular degradation of apo BL and apo E is not primarily responsible for the observed reduction in apolipoprotein secretion in hepatocytes derived from diabetic rats.
Very little apo BH was synthesized in pulse-chase studies by hepatocytes derived from diabetic rats compared with controls limiting our ability to assess translational parameters and recovery of apo BH. Consistent with its reduced synthesis, labeled apo BH is almost completely absent from steady state labeled hepatocytes derived from diabetic rats compared with its presence in control hepatocytes (22) . One explanation for this finding could be that most of the apo B mRNA present in livers of diabetic rats is BSTOP and contains the translational stop codon. This possibility is unlikely since direct analysis of BGLN and BSTOP indicates that the proportion of the message coding for apo BH is normal in diabetic liver. However, the percentage of apo BGLN mRNA is of the total cellular apo B mRNA and it is possible that a portion ofthe BGLN message is sequestered in an inactive form. Another possibility is that differences in translational efficiency may be involved considering the twofold larger size of the translation sequence of apo BH compared to apo BL.
Ribosome transit studies were undertaken to explore the possibility that the defect in translation we observed for apo B and apo E in the diabetic state was related to a prolongation in peptide elongation. Using the isotope ratio method outlined by Palmiter (57) with modifications for use in cultured cells (58) , the ribosome transit time is independent of the rates of attachment of ribosomes to mRNA and the number of polyribosomes. The ribosome transit time for total soluble protein for control hepatocytes was similar to that reported for suspensions of control hepatocytes (59) , and apo B transit time is similar to reported values (67) . A prolonged transit time for total soluble protein was not observed in diabetic rats by others (59) , in contrast to presented results. The reasons for this difference are not known, although experimental conditions differ. We used streptozotocin, compared with alloxan, to induce hypoinsulinemic diabetes, and primary cultures of hepatocytes were used instead of acute suspension cultures. Moreover, we used a double label method employing ratios of 3H and 14C label in both long and short times, compared with the use of a single label. The total protein transit time increased from 3.6 to 6.7 min (difference of 3.1 min), compared with apo E which increased from 3.1 to 8.1 min (difference of 5 min) and apo B which increased from 9.3 to 38 min (difference of29 min). Apo B was increased more than four times the control which is even more dramatic when expressed as total transit time. These results suggest there are factors specific for apo B, one of which may be the unusual length ofthe mRNA, which are responsible for the dramatically prolonged elongation. Consistent with this finding is the almost complete inability to translate apo BH in spite of available mRNA in the diabetic rat.
Regulatory events that could affect polypeptide chain elongation include changes in activities of elongation factors, variations in the secondary structure of mRNA, as well as changes in the physical properties of the membranes to which ribosomes become attached. There is also the possibility that peptide elongation could be affected by the conformation of the growing peptide chain which could be altered by cotranslational modifications such as fatty acylation and phosphorylation. Considering the unique role of apo B as a lipid binding and transport protein, cotranslational modification of apo B might play an important role in controlling translational efficiency, as lipid assembly may be obligatory for efficient apo B translation. There are known changes in diabetes, including decreased lipid synthesis (30, 41) and increased apo B phosphorylation (68), which could play a part in the control of apo B translational efficiency.
Selective reduction in hepatic secretory proteins in hypoinsulinemic diabetes including apo B and apo E could relate to involvement ofmRNA associated proteins (mRNPs) in modulating specific changes in mRNA translational efficiency. Proteins, bound by mRNAs, are believed to maintain specific messages in either a translatable or nontranslatable state, and may be important in the association of mRNAs with the cytoskeletal elements of the cell (69) . It is of interest that recent studies employing apo B mRNA sequences and rat liver S100 cytosolic extracts indicate that a portion of hepatic apo B mRNA is present in liver as a macromolecular, mRNP complex (70) . This complex is believed to be important for the editing of the specific glutamine codon introducing a translational stop codon. How much apo B mRNA in liver is associated with the complex (nuclear or cytoplasmic) and whether the complex allows for simultaneous translation of the apo B mRNA is unknown.
The mechanisms of development of hyperlipoproteinemia in experimental diabetes and their relationships to mechanisms involved in hyperlipoproteinemia associated with human diabetes mellitus is controversial (30, 71) . Studies in experimental models of diabetes demonstrate that insulin deficiency lowers hepatic apo B (28, 29) and VLDL-triglyceride secretion (40, 41) , and with long-term insulin treatment in vivo, hepatic apo B production normalizes (28) . Our studies suggest a positive correlation between plasma insulin levels and hepatic triglyceride-rich lipoprotein production, and such a correlation is supported by studies which raise ambient plasma levels by insulin injection (72) , continuous insulin infusion (73) , and sucrosefeeding (74) . Current studies support the concept that there is an insulin-dependent process which is important in hepatic apo B and apo E production. The positive relationship between ambient insulin levels and hepatic lipoprotein-apo B production contrasts with results of short-term studies in primary rat hepatocyte cultures (25-28) and in rat liver perfusion (28) which demonstrate that high levels of insulin inhibit hepatic apo B and VLDL secretion. The insulin inhibition of hepatic VLDL formation occurs at concentrations ofinsulin consistent with postprandial portal levels, and is reversible after withdrawal of insulin (25). We have shown previously (26) that the insulin effect on apo B is not synchronous with insulin-stimulated lipid synthesis. At low concentrations (0.1 nM), insulin stimulates lipid synthesis from acetate, and at higher concentrations (> 10 nM), while continuing to stimulate lipid synthesis, insulin inhibits VLDL particle secretion ofboth apo B and triglyceride components (26). Recent studies suggest that triglyceride accumulates in insulin-treated hepatocytes as cytoplasmic droplets (75) and not as preassembled lipoproteins, consistent with the lack of accumulation of cellular apo B in insulin-treated hepatocytes (22) . We have recently shown that the primary mechanism involved in the suppressive effect of insulin on apo B secretion by liver is an effect on intracellular degradation of freshly synthesized apo B (22) , a component of VLDL that is obligatory for lipoprotein formation. The insulin effect favors apo BH (B-I00) degradation, compared with apo BL (B-48) (22) . We hypothesize that the insulin degradation pathway relates to cyclical suppression of hepatic VLDL production to minimize competition of catabolic pathways in the postprandial state. We found little evidence for apo B (apo BL) degradation in hepatocytes derived from diabetic rats consistent with their hypoinsulinemic state. From current and previous studies it is clear that there are both long-term and shortterm insulin-dependent regulatory mechanisms involved in the control of hepatic VLDL apo B production (28, 76) .
Experimental diabetes in rats also affects VLDL particle composition (29) (30) (31) 36 ) with a marked reduction in apo E. Considering the role of apo E in removal of both hepatic and intestinal triglyceride-rich lipoproteins (37), it is important to explore the potential for additional catabolic defects in diabetic states created by altered particle composition resultant from changes in hepatic apo E production. Initial experiments involving apo E in the current study suggest that there are decreases in hepatic apo E secretion which could have such an effect. We present evidence that reduced apo E production is primarily a result of slowed translation similar to apo B, and not the result of decreased mRNA levels or increased intracellular apo E degradation. Regulation of hepatic apo E mRNA levels is complex. In regenerating rat liver, apo E mRNA levels are decreased due to both transcriptional and posttranscriptional mechanisms (77) . In development, hepatic apo E mRNA is also low and progressively increases to adult levels shortly after birth (78) . In adult rats, dexamethasone treatment does little to affect hepatic apo E mRNA (78) , and in primary cultures of rat hepatocytes apo E mRNA is relatively stable to the presence ofdexamethasone, insulin, and insulin, plus dexamethasone in the media (78) . Secretion of apo E is greatly enhanced when hepatocytes are cultured in media containing insulin plus dexamethasone (79) consistent with translational control.
An important preliminary observation is the responsiveness of apo B and albumin mRNA to insulin treatment in the diabetic state. Hepatic apo E mRNA did not increase using this same treatment protocol. Although apo A-I metabolism was not comprehensively studied, preliminary blotting analysis for apo A-I mRNA indicates that insulin treatment significantly lowered apo A-I mRNA in treated diabetic rats, compared with diabetic rats [68±9 versus 153±31, as a percent of control and calculated as described in Table VI, P < 0.007]. These results suggest that insulin treatment ofthe diabetic state has different effects on different apolipoprotein mRNAs. Interestingly, apo B production in liver perfusions of treated diabetic rats was normalized (28) , and not increased after insulin treatment in vivo suggesting the involvement of additional factors other than mRNA abundance in regulation of apo B production by liver in treated diabetic rats.
The investigation of factors such as free fatty acid supply or mode of insulin administration, which may be involved in the regulation ofhepatic lipoprotein production in treated diabetic rats, must be fully evaluated before attempting to relate the current results of insulin treatment of diabetic rats to humans. Although hepatic apo B mRNA increased with insulin administration to diabetic rats, treatment by insulin injection is nonphysiologic and likely results in systemic hyperinsulinemia (72) , as opposed to cyclic portal release of insulin. In addition, in treated diabetics there are higher insulin levels in the peripheral circulation, unlike normal postprandial insulin that is pre-dominantly portal. Increased hepatic apo B mRNA also occurs in hypothalamus-lesioned obese rats that are known to be hypennsulinemic (17) . The current studies demonstrate the insulin responsiveness of hepatic apo B mRNA levels at least in the environment of diabetes.
Our results support differences in long-term and short-term effects of insulin on VLDL metabolism, and suggest a necessary role for insulin in the regulation of hepatic triglyceriderich lipoprotein production.
